We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New 3D-Printable Materials for Reconstructive Surgery Can Be Monitored Using X-Ray or CT

By HospiMedica International staff writers
Posted on 23 Feb 2024

Over the past decade, gelatin-based materials have captured significant attention in research due to their simplicity in production, non-toxic nature, affordability, biodegradability, and crucially, their ability to facilitate cell growth. More...

These attributes make them highly suitable for use in plastic and reconstructive surgery. When a surgeon implants such material into a wound, the body progressively decomposes it and substitutes it with its own tissue. This process not only expedites wound healing but also allows for the reshaping of tissues, such as in breast reconstruction post-mastectomy. Additionally, these materials are valuable for 3D printing custom implants for individual patients. Despite these advantages, there has been a significant challenge: tracking the degradation of these materials in the body has been problematic with traditional imaging techniques.

Researchers from IOCB Prague (Prague, Czech Republic) and Ghent University (Ghent, Belgium) have been refining the properties of gelatin-based materials and have introduced 3D-printable materials that are easily trackable using X-ray machines or computed tomography (CT). By incorporating a radiopaque (X-ray-contrast) agent, they have enabled the observation of the rate at which implants shrink and whether they sustain any damage. A whole series of academic papers is being written on this topic. The initial paper introduced a gelatin-based material visible via magnetic resonance imaging (MRI). The most recent publication describes materials that are detectable with X-ray and CT imaging.

This advancement allows for the ongoing monitoring of these implants, observing their biodegradation and identifying potential mechanical failures. Such data are immensely valuable in clinical settings. Leveraging this information, the biodegradation of implants can be customized to align with specific clinical needs. This is vital because tissue growth rates vary across the human body, necessitating the adaptation of implant properties accordingly. The ultimate aim is to align the biodegradation rate of these implants with the growth rate of healthy tissue. In light of these innovations, the two collaborating institutions have filed a joint patent application for the use of these materials in plastic and reconstructive surgery.

Related Links:
IOCB Prague
Ghent University


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.